Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...
Thousands of women who have had breast cancer feel “forgotten” as they are paying up to €102 a month for menopause treatments ...
Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.
The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
The approval of datopotamab deruxtecan, a novel TROP2-directed antibody drug conjugate, marks a major therapeutic milestone and provides patients with metastatic breast cancer a new treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback